Endocrinology, Vol 103, 1054-1066, Copyright © 1978 by Endocrine Society

ARTICLES

Alterations in insulin binding induced by changes in vivo in the levels of glucocorticoids and growth hormone

CR Kahn, ID Goldfine, DM Neville Jr and P De Meyts

Previous studies have shown that the sensitivity of tissues to insulin is diminished in states of glucocorticoid and GH excess and is increased when these hormones are deficient. To evaluate the role of the insulin receptor in these states, we have studied [125I]insulin binding to purified liver plasma membranes obtained from rats with a variety of perturbations of both glucocorticoids and GH. Glucocorticoid excess was produced in rats by administration of ACTH (40 U/day for 4 days) or dexamethasone (1 mg/day for 4 days). This resulted in an insulin-resistant state. Associated with this insulin resistance, there was a 50-60% decrease in insulin binding to its specific receptors in liver. Conversely, adrenalectomy, which produces an increase in insulin sensitivity, was associated with an increase in insulin binding to liver. Computer-assisted Scatchard analysis using a negative cooperative model for the inulin-receptor interaction indicated that, in contrast to our findings with obesity, the changes in insulin binding in these states were most likely due entirely to changes in receptor affinity, with no change in receptor concentration. GH administration also produced mild insulin resistance and a decrease in receptor concentration. This was associated with a reciprocal increase in receptor affinity and thus, no major alteration in insulin binding occurred at low physiological insulin concentrations. Hypophysectomized rats, on the other hand, showed an increase in receptor concentration and a decrease in affinity, and GH treatment only partially corrected these changes. Rats implanted with the MtT tumor (which secretes ACTH, GH, and PRL) have the combined effects of excess glucocorticoids and GH and are very insulin resistant. Liver membranes prepared from these rats showed a decrease in insulin binding and receptor affinity similar to that observed in other states of glucocorticoid excess. Further, adrenalectomy of the tumor-bearing rats resulted in an increase in insulin binding despite the persistence of the elevated levels of GH, ACTH, and PRL. These findings suggest that alterations in insulin receptor affinity and number may play a major role in the states of altered insulin sensitivity which accompany glucocorticoid excess and deficiency, and follow hypophysectomy. In contrast, the insulin resistance associated with GH excess is mediated at either a site on the receptor distal to the insulin-binding site (i.e. transduction) or at one or more of the intracellular reactions important in insulin action.

This article has been cited by other articles:

				A. McDonald, R. M Williams, F. M Regan, R. K Semple, and D. B Dunger IGF-I treatment of insulin resistance Eur. J. Endocrinol., August 1, 2007; 157(suppl_1): S51 - S56. [Abstract] [Full Text] [PDF]

				K. Y. Hur, M. S. Kim, Y. S. Kim, E. S. Kang, J. H. Nam, S. H. Kim, C. M. Nam, C. W. Ahn, B. S. Cha, S. I. Kim, et al. Risk Factors Associated With the Onset and Progression of Posttransplantation Diabetes in Renal Allograft Recipients Diabetes Care, March 1, 2007; 30(3): 609 - 615. [Abstract] [Full Text] [PDF]

				H. M. Hammon, C. Philipona, Y. Zbinden, J. W. Blum, and S. S. Donkin Effects of Dexamethasone and Growth Hormone Treatment on Hepatic Gluconeogenic Enzymes in Calves J Dairy Sci, June 1, 2005; 88(6): 2107 - 2116. [Abstract] [Full Text] [PDF]

				M. F. Nielsen, A. Caumo, V. Chandramouli, W. C. Schumann, C. Cobelli, B. R. Landau, H. Vilstrup, R. A. Rizza, and O. Schmitz Impaired basal glucose effectiveness but unaltered fasting glucose release and gluconeogenesis during short-term hypercortisolemia in healthy subjects Am J Physiol Endocrinol Metab, January 1, 2004; 286(1): E102 - E110. [Abstract] [Full Text]

				A. M. Kanaya, D. Herrington, E. Vittinghoff, F. Lin, D. Grady, V. Bittner, J. A. Cauley, and E. Barrett-Connor Glycemic Effects of Postmenopausal Hormone Therapy: The Heart and Estrogen/progestin Replacement Study: A Randomized, Double-Blind, Placebo-Controlled Trial Ann Intern Med, January 7, 2003; 138(1): 1 - 9. [Abstract] [Full Text] [PDF]

				N. Shojima, H. Sakoda, T. Ogihara, M. Fujishiro, H. Katagiri, M. Anai, Y. Onishi, H. Ono, K. Inukai, M. Abe, et al. Humoral Regulation of Resistin Expression in 3T3-L1 and Mouse Adipose Cells Diabetes, June 1, 2002; 51(6): 1737 - 1744. [Abstract] [Full Text] [PDF]

				F. P. Dominici and D. Turyn Growth Hormone-Induced Alterations in the Insulin-Signaling System Experimental Biology and Medicine, March 1, 2002; 227(3): 149 - 157. [Abstract] [Full Text] [PDF]

				S. E. la Fleur, A. Kalsbeek, J. Wortel, M. L. Fekkes, and R. M. Buijs A Daily Rhythm in Glucose Tolerance: A Role for the Suprachiasmatic Nucleus Diabetes, June 1, 2001; 50(6): 1237 - 1243. [Abstract] [Full Text]

				P. M. Piatti, L. D. Monti, A. Caumo, M. Conti, F. Magni, M. Galli-Kienle, E. Fochesato, A. Pizzini, L. Baldi, G. Valsecchi, et al. Mediation of the Hepatic Effects of Growth Hormone by Its Lipolytic Activity J. Clin. Endocrinol. Metab., May 1, 1999; 84(5): 1658 - 1663. [Abstract] [Full Text]

				S Schwarz, P Pohl, and G. Zhou Steroid binding at sigma-"opioid" receptors Science, December 22, 1989; 246(4937): 1635 - 1637. [PDF]